Lupin Limited

Sector: Pharmaceuticals  |  HQ: Mumbai, Maharashtra  |  Founded: 1968  |  Employees: ~22,000

Listed as: NSE / BSE listed  |  NSE / BSE  |  Ticker: LUPIN.NS  |  Website →

Key people

• Vinita Gupta (CEO)
• Nilesh Gupta (Managing Director)

Company overview

Lupin Limited is one of India's top-5 pharmaceutical companies. Founded in 1968 in Mumbai, Lupin operates 14 manufacturing facilities globally. FY25 revenue was approximately ₹21,500 crore. Lupin has a meaningful US generics business, a strong India domestic franchise, and an emerging biosimilars and specialty portfolio.

Business model

India domestic, US generics, Emerging Markets, EMEA, and API (sold through Lupin Atharv Ability).

Operating segments

Recent developments

May 2026

Lupin's regulatory activity intensified in Q1-Q2 FY2026, with multiple FDA drug approvals and tentative approvals advancing its pipeline. The company received final FDA approval for Famotidine Injection, USP in May 2026 [5], alongside tentative approvals for Revefenacin Inhalation Solution in May 2026 [1] and Pitolisant Tablets in March 2026 [8]. Lupin also launched Favipiravir under the brand Covihalt® for mild-to-moderate COVID-19 treatment in May 2026 [2]. Meanwhile, the company's FY2026 and Q4 FY2026 financial results were released in May 2026, providing an update on overall performance [3].

On the manufacturing front, four of Lupin's Indian facilities successfully cleared FDA inspections, receiving Establishment Inspection Reports (EIRs): Goa (Feb 2026) [10], Aurangabad (Feb 2026) [7], Vizag API (Feb 2026) [9], and Mandideep Unit II (Feb 2026) [4]. These clearances across multiple sites underscore robust quality compliance. Separately, Lupin Manufacturing Solutions announced expansion of its Dabhasa, India facility in March 2026 [6], signalling investment in production capacity to support future growth.

Sources (10)

1. Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution - Lupin | Press Release - lupin.com · lupin.com · Tue, 19 May 2026
2. Lupin Launches Favipiravir Drug Covihalt® for Treatment of Mild to Moderate COVID-19 - Lupin | Press Release - lupin.com · lupin.com · Fri, 15 May 2026
3. Lupin FY2026 and Q4 FY2026 Results - Lupin | Press Release - lupin.com · lupin.com · Thu, 07 May 2026
4. Lupin’s Mandideep Unit II Facility Receives EIR from U.S. FDA - Lupin | Press Release - lupin.com · lupin.com · Sat, 07 Feb 2026
5. Lupin Receives U.S. FDA Approval for Famotidine Injection, USP - Lupin | Press Release - lupin.com · lupin.com · Thu, 14 May 2026
6. Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India - lupin.com · lupin.com · Thu, 19 Mar 2026
7. Lupin’s Aurangabad Facility Receives EIR from U.S. FDA - Lupin | Press Release - lupin.com · lupin.com · Sat, 07 Feb 2026
8. Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets - Lupin | Press Release - lupin.com · lupin.com · Wed, 25 Mar 2026
9. Lupin’s Vizag API Facility Receives EIR from U.S. FDA - Lupin | Press Release - lupin.com · lupin.com · Sat, 07 Feb 2026
10. Lupin Receives EIR from US FDA for its Goa Facility - Lupin | Press Release - lupin.com · lupin.com · Fri, 27 Feb 2026

Financial performance and recent trajectory

Lupin FY25 revenue ₹21,500 crore with EBITDA margin recovering to 19-21 percent from FY22 lows. The Gupta family is the founding promoter group.

Stock performance and shareholder context

Lupin (NSE: LUPIN, BSE: 500257). Promoter holding approximately 47 percent.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Top-5 Indian pharma. Strong India domestic (5-6 percent IPM share). Growing complex-generic and biosimilar pipeline.

Key risks

US FDA inspection; complex-generic competition; biosimilar pipeline execution.

Outlook

Specialty branded launches and biosimilars are the key catalysts through FY28.

KAMRIT point of view

Building or competing with Lupin?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Lupin and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 2 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Lupin Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.